136 related articles for article (PubMed ID: 38564986)
21. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
Stein EM
Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
[TBL] [Abstract][Full Text] [Related]
22. Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.
Klink AJ; Gajra A; Knoth RL; Marshall L; Hou Y; McBride A; Copher R
Leuk Res; 2022 Nov; 122():106946. PubMed ID: 36108427
[TBL] [Abstract][Full Text] [Related]
23. Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
Roboz GJ
Clin Adv Hematol Oncol; 2018 May; 16(5):322-325. PubMed ID: 29851927
[No Abstract] [Full Text] [Related]
24. Enasidenib: First Global Approval.
Kim ES
Drugs; 2017 Oct; 77(15):1705-1711. PubMed ID: 28879540
[TBL] [Abstract][Full Text] [Related]
25. Therapy for isocitrate dehydrogenase 2 (IDH2)
Linch DC; Hills RK; Burnett AK; Russell N; Gale RE
Br J Haematol; 2022 Mar; 196(6):1348-1352. PubMed ID: 34870324
[TBL] [Abstract][Full Text] [Related]
26. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.
Montesinos P; Fathi AT; de Botton S; Stein EM; Zeidan AM; Zhu Y; Prebet T; Vigil CE; Bluemmert I; Yu X; DiNardo CD
Blood Adv; 2024 May; 8(10):2509-2519. PubMed ID: 38507688
[TBL] [Abstract][Full Text] [Related]
27. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
28. IDH2 inhibition in AML: Finally progress?
Stein EM
Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
[TBL] [Abstract][Full Text] [Related]
29. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.
Green CL; Evans CM; Zhao L; Hills RK; Burnett AK; Linch DC; Gale RE
Blood; 2011 Jul; 118(2):409-12. PubMed ID: 21596855
[TBL] [Abstract][Full Text] [Related]
30. Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.
Song A; Altabbakh O; Sallman DA; Padron E; Talati C; Hussaini MO
Eur J Haematol; 2021 Dec; 107(6):609-616. PubMed ID: 34407254
[TBL] [Abstract][Full Text] [Related]
31. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L; David MD; Kennedy A; Metzner M; Amatangelo M; Shih A; Stoilova B; Quivoron C; Heiblig M; Willekens C; Saada V; Alsafadi S; Vijayabaskar MS; Peniket A; Bernard OA; Agresta S; Yen K; MacBeth K; Stein E; Vassiliou GS; Levine R; De Botton S; Thakurta A; Penard-Lacronique V; Vyas P
Nat Med; 2018 Aug; 24(8):1167-1177. PubMed ID: 30013198
[TBL] [Abstract][Full Text] [Related]
32. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai SF; Huang Y; Lance JR; Mao HC; Dunbar AJ; McNulty SN; Druley T; Li Y; Baer MR; Stock W; Kovacsovics T; Blum WG; Schiller GJ; Olin RL; Foran JM; Litzow M; Lin T; Patel P; Foster MC; Boyiadzis M; Collins RH; Chervin J; Shoben A; Vergilio JA; Heerema NA; Rosenberg L; Chen TL; Yocum AO; Druggan F; Marcus S; Stefanos M; Druker BJ; Mims AS; Borate U; Burd A; Byrd JC; Levine RL; Stein EM
Blood Adv; 2024 Jan; 8(2):429-440. PubMed ID: 37871309
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Thol F; Damm F; Wagner K; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Heil G; Heuser M; Krauter J; Ganser A
Blood; 2010 Jul; 116(4):614-6. PubMed ID: 20421455
[TBL] [Abstract][Full Text] [Related]
34. Positive First Trial of Enasidenib for AML.
Cancer Discov; 2017 Aug; 7(8):OF1. PubMed ID: 28659444
[TBL] [Abstract][Full Text] [Related]
35. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
[TBL] [Abstract][Full Text] [Related]
36. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
37. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
Bill M; Jentzsch M; Bischof L; Kohlschmidt J; Grimm J; Schmalbrock LK; Backhaus D; Brauer D; Goldmann K; Franke GN; Vucinic V; Niederwieser D; Mims AS; Platzbecker U; Eisfeld AK; Schwind S
Blood Adv; 2023 Feb; 7(3):436-444. PubMed ID: 35381077
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
39. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
DiNardo C
Clin Adv Hematol Oncol; 2018 Apr; 16(4):247-249. PubMed ID: 29742078
[No Abstract] [Full Text] [Related]
40. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
